Taurus Asset Management LLC lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,054 shares of the biopharmaceutical company’s stock after selling 73 shares during the quarter. Regeneron Pharmaceuticals accounts […]
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
31.05.2024 - Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, .
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved.
Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3.